C
Claudia Blattmann
Researcher at Heidelberg University
Publications - 37
Citations - 882
Claudia Blattmann is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 22 publications receiving 706 citations. Previous affiliations of Claudia Blattmann include German Cancer Research Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Michal Kovac,Claudia Blattmann,Sebastian Ribi,Jan Smida,Nikola S. Mueller,Florian Engert,Francesc Castro-Giner,Joachim Weischenfeldt,Monika Kovacova,Andreas H. Krieg,Dimosthenis Andreou,Per-Ulf Tunn,Hans Roland Dürr,Hans Rechl,Klaus-Dieter Schaser,Ingo Melcher,Stefan Burdach,Andreas E. Kulozik,Katja Specht,Karl Heinimann,Simone Fulda,Simone Fulda,Stefan S. Bielack,Gernot Jundt,Ian Tomlinson,Jan O. Korbel,Michaela Nathrath,Daniel Baumhoer +27 more
TL;DR: It is implied that multiple oncogenic pathways drive chromosomal instability during osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be therapeutically exploited.
Journal ArticleDOI
Advances in the management of osteosarcoma.
TL;DR: Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases, with a very limited number of active agents available.
Journal ArticleDOI
Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition
Claudia Blattmann,Susanne Oertel,Volker Ehemann,Markus Thiemann,Peter E. Huber,Peter E. Huber,Marc Bischof,Olaf Witt,Olaf Witt,Hedwig E. Deubzer,Hedwig E. Deubzer,Andreas E. Kulozik,Jürgen Debus,Klaus J. Weber +13 more
TL;DR: Results show that HDACIs enhance radiation action in OS and RMS cell lines, and inhibition of DNA repair, as well as increased apoptosis induction after exposure toHDACIs, can be mechanisms of radiosensitization by HDACI.
Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase inhibition
Claudia Blattmann,Susanne Oertel,Volker Ehemann,Markus Thiemann,Peter E. Huber,Peter E. Huber,Marc Bischof,Olaf Witt,Olaf Witt,Hedwig E. Deubzer,Hedwig E. Deubzer,Andreas E. Kulozik,Jürgen Debus,Klaus J. Weber +13 more
TL;DR: In this article, the authors examined the effect of HDACIs on cell proliferation and clonogenic survival in osteosarcoma cell lines and showed that SAHA significantly increased radiation-induced apoptosis in the OS cell lines, whereas in the RMS cell lines radiation-induced apoptosis was insignificant with and without SAHA.
Journal ArticleDOI
Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma
Claudia Blattmann,Susanne Oertel,Daniela Schulz-Ertner,Stefan Rieken,Sabine Haufe,Volker Ewerbeck,Andreas Unterberg,Irini Karapanagiotou-Schenkel,Stephanie E. Combs,Anna Nikoghosyan,Marc Bischof,Oliver Jäkel,Peter E. Huber,Andreas E. Kulozik,Jürgen Debus +14 more
TL;DR: This is a monocenter, single-arm study for patients ≥ 6 years of age with non-resectable osteosarcoma to improve outcome and the determination of feasibility and toxicity of HIT.